Clinical Trial Detail

NCT ID NCT02650752
Title Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Her2-receptor positive breast cancer

Therapies

Capecitabine + Lapatinib

Age Groups: senior adult

Additional content available in CKB BOOST